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May 14, 2013:2021–6assay (either of brain NP [BNP] or of the N-terminal fragment of
BNP [NT-proBNP]) in complex congenital defects (congenital
heart disease [CHD]). Their literature review is mostly focused on
the applications of NPs for the follow-up of some CHD (1).
However, we would like to remind that NPs may be also used for
neonatal screening purposes (2,3), differential diagnosis, prognos-
tic stratification (in children undergoing cardiac surgery) (2,4), and
to guide the surgical/medical management of CHD, including
complex defects (2), as it is the case for the setting of heart
failure (5).
Moreover, variability associated with both physiological and
methodological sources is a relevant issue to be taken into account
for proper clinical use of NPs in patients of pediatric age.
In particular, NP levels in healthy subjects are very high during
the first 4 days of life, while decreasing thereafter, rapidly through-
out the first week, with a further slow progressive reduction for up
to the first month of life (6). After the first month of life, NPs
show no more significant age- or gender-related differences up to
puberty (2,6).
Furthermore, the measured NP concentrations, as well as
reference ranges and decisional cutoff values, are strictly method
dependent (5). The diagnostic accuracy of NPs in neonates with
CHD, too, varies up to the first month of life, with low levels in
the first 3 days after birth (2). These findings are likely due to the
different timecourse of NP levels observed either in healthy
neonates or in newborns with CHD. In the first 3 days of life,
BNP levels are very high in both healthy subjects and patients,
whereas after the fourth day peptide levels rapidly and progres-
sively fall only in healthy neonates. For these reasons, we have
suggested two different cutoff values to rule in or out CHD: the
first, characterized by higher values from 1 to 3 days of life; and the
second with lower values from days 4 to 30 of life (2). Further-
more, because various methods have been employed by different
authors (1,2), the influence of the analytical contribution to
BNP/NT-proBNP concentration variability, by the assay method,
needs to be evaluated (2).
In conclusion, the assay of NPs may be considered as helpful for
screening, diagnostic, prognostic, and follow-up purposes, to be
included into an integrated approach to children with suspected or
ascertained complex CHD. Nevertheless, biological (age-related)
and method-related variability needs to be taken into account
when interpreting NP values in this setting, especially in the
neonatal age.
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Reply
We thank Dr. Cantinotti and colleagues for their interest in our
article (1) and for their valuable addition. We fully agree with
Cantinotti et al. that brain natriuretic peptides (NPs) are of
potential use for other purposes as differential diagnosis and to
guide medical and surgical management of congenital heart disease
(CHD). In our systematic review we aimed to provide a clear
overview of average NP levels for the 3 most commonly encoun-
tered complex congenital heart defects and the relation with
cardiac function to determine its possible use in the cardiologists’
daily practice. The use of this biomarker at young pediatric age is
so far mainly studied in mixed cohorts of various forms of CHD
(2). As we looked at disease-specific NP values, these studies were
not included in our review article. Nevertheless, daily changes in
BNP in the first days of life and suggested cutoff values for NPs in
this period clearly provide valuable diagnostic information for both
neonatologists and pediatric cardiologists.
Cantinotti et al. also note that the various assay methods used to
determine NP levels measure different NP concentrations and have
assay method–specific cutoff values (3).We acknowledge this fact, and
it was our main reason to withhold us from a direct comparison of the
observed NP values by performing a formal meta-analysis. By report-
ing both NP values for CHD patients and, when reported, NP values
for healthy controls per study (Figure 2 [1]), we aimed to demonstrate
the observed differences objectively without drawing any overall
conclusions. Despite known differences between assay kits, the mea-
sured NP levels and observed correlations were comparable, strength-
ening the potential clinical use of NPs in CHD (1). Furthermore, the
dditional prognostic value of the marker remains to be clarified by
arger longitudinal studies.
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Appropriate Use Criteria
to Reduce Underuse and
Overuse of Revascularization
Although the appropriate use criteria (AUC) for the performance
of revascularization are well meaning, important limitations in-
clude the facts that they: 1) represent the consensus of a limited
group of stakeholders; 2) classify a minority of possible permuta-
tions of patient scenarios; 3) do not incorporate essential data
points, including specific lesion characteristics, extent of myocar-
dium supplied, fractional flow reserve and intravascular ultrasound
data, and important comorbidities (diabetes mellitus, chronic
kidney disease, and so forth); 4) are based on data recording in the
National Cardiovascular Data Registry by persons with widely
variable training and motivation without systematic monitoring,
adjudication, or audit; 5) undervalue quality of life issues, and in
this regard, ignore patient preferences; and 6) do not emphasize
underuse of percutaneous coronary intervention (1–4).
In this regard, Ko et al. (5) report that almost one-third of
ubjects undergoing angiography in Ontario, Canada, between
pril 2006 and March 2007 deemed “appropriate” by U.S. AUC
riteria were not revascularized. Such patients experienced appre-
iably worse clinical outcomes (increased incidence of death or
cute coronary syndrome presentation) through 3-year follow-up
hazard ratio [HR] of revascularization vs. medical therapy: 0.61;
5% confidence interval [CI]: 0.42 to 0.88). In the accompanying
ditorial, Patel (6) states: “This reduction in clinical events was not
een in patients with a revascularization classification (appropri-
teness score) of uncertain (HR: 0.57; 95% CI: 0.28 to 1.16) or
nappropriate (HR: 0.99; 95% CI: 0.48 to 2.02)” (6).
Although we agree with Dr. Patel regarding the apparent lack of
enefit associated with revascularization (vs. medical therapy) in
ubjects scored as inappropriate (at least as regards death or new
cute coronary syndrome, although chronic angina and quality of
ife data were not collected), we disagree with the conclusion for
he “uncertain” patients. Given the point estimate and confidence
nterval, this may well represent type II error. As evident from the
early identical HRs, the magnitude of benefit provided by
evascularization (vs. medical therapy) may be at least as great
mong the “uncertain” and “appropriate” classified cohorts, but was
bscured by the relative lack of power (only 326 subjects classified
s uncertain vs. 991 subjects classified as appropriate). Upsizing the
ncertain cohort to 991 subjects, with proportionally similar event
ates for revascularized (8%; 43 events) and medically treated(15.3%; 70 events) subjects, results in an odds ratio for revascular-
ization (vs. medical therapy) of 0.48 (95% CI: 0.31 to 0.73), a
highly statistically significant difference. Thus, on the basis of this
report, larger studies are warranted to determine whether the
spectrum of patients benefitting from revascularization should
expand to include the uncertain group (which would further
enlarge the specter of underuse).
*Dean J. Kereiakes, MD
Gregg W. Stone, MD
*The Christ Hospital Heart and Vascular Center
The Lindner Research Center
2123 Auburn Avenue, Suite 424
Cincinnati, Ohio 45219
E-mail: lindner@thechristhospital.com
http://dx.doi.org/10.1016/j.jacc.2012.12.052
EFERENCES
1. Stone GW, Moses JW. Interventional cardiology: how should the
appropriateness of PCI be judged? Nat Rev Cardiol 2011;8:544–6.
2. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific
evidence underlying the ACC/AHA clinical practice guidelines. JAMA
2009;301:831–41.
3. Chan PS, Brindis RG, Cohen DJ, et al. Concordance of physician
ratings with the appropriate use criteria for coronary revascularization.
J Am Coll Cardiol 2001;57:1546–53.
4. Marso SP, Teirstein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA.
Percutaneous coronary intervention use in the United States: defining
measures of appropriateness. J Am Coll Cardiol Intv 2012;5:229–35.
5. Ko DT, Guo H, Wijeysundera HC, et al., for the Cardiac Care
Network (CCN) of Ontario Variations in Revascularization Practice in
Ontario (VRPO) Working Group. Assessing the association of appro-
priateness of coronary revascularization and clinical outcomes for
patients with stable coronary artery disease. J Am Coll Cardiol 2012;
60:1876–84.
6. Patel MR. Appropriate use criteria to reduce underuse and overuse:
striking the right balance. J Am Coll Cardiol 2012;60:1885–7.
Reply
We appreciate the insightful comments provided by Drs. Kere-
iakes and Stone on our study (1). Applying the appropriate use
criteria of coronary revascularization on patients with stable coro-
nary artery disease afforded new insights on the potential overuti-
lization, underutilization, and uncertain use of coronary revascu-
larization in contemporary practice (2). In our population-based
cohort assembled in Ontario, Canada, we observed the majority
(68%) of coronary revascularizations were considered appropriate,
18% were considered uncertain, and 14% were considered inap-
propriate. Among patients who had appropriate indications, we
found that coronary revascularization was associated with a 39%
lower hazard of adjusted death or repeat acute coronary syndrome
at 3 years. We also observed that 31% of patients in the appropriate
category did not receive revascularization, suggesting that under-
utilization of therapy is still prevalent in clinical practice. In
contrast, patients who had inappropriate indications and received
coronary revascularization or medical therapy had no significant
difference in hazard of death or acute coronary syndrome, suggest-
ing potential overutilization of coronary revascularization in this
subgroup. Finally, many clinical scenarios in the appropriateness
